@article{27573cac9d994fb5b61967d36e7b61b9,
title = "Cyclin E2: A novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle",
abstract = "We report here the cloning and characterization of human and mouse cyclin E2, which define a new subfamily within the vertebrate E-type cyclins, while all previously identified family-members belong to the cyclin E1 subfamily. Cyclin E2/CKD2 and cyclin E/CDK2 complexes phosphorylate histone H1 in vitro with similar specific activities and both are inhibited by p27(Kip1). Cyclin E2 mRNA levels in human cells oscillate throughout the cell cycle and peak at the G1/S boundary, in parallel with the cyclin E mRNA. In cells, cyclin E2 is complexed with CDK2, p27 and p21. Like cyclin E, cyclin E2 is an unstable protein in vivo and is stabilized by proteasome inhibitors. Cyclin E2-associated kinase activity rises in late G1 and peaks very close to cyclin E activity. In two malignantly transformed cell lines, cyclin E2 activity is sustained throughout S phase, while cyclin E activity has already declined and cyclin A activity is only beginning to rise. We speculate that cyclin E2 is not simply redundant with cyclin E, but may regulate distinct rate-limiting pathway(s) in G1-S control.",
keywords = "CDK2, Cyclin E, Cyclin E2, p27(Kip1)",
author = "Nathalie Lauper and Beck, {Andreas R.P.} and Sandrine Cariou and Larry Richman and Kay Hofmann and Walter Reith and Slingerland, {Joyce M.} and Bruno Amati",
note = "Funding Information: We are particularly grateful to Yue Xiong and Maimoona Zariwala for sharing their observations on cyclin E2 prior to publication. We are indebted to Viesturs Simanis for his help with the use of the elutriator, Trevor Littlewood for his help with peptides and antibodies and John Pichione for his help and dedication in solving computing problems. We thank Steve Dalton, Nic Jones, Gunvanti Patel and Richard Treisman for the gift of yeast strains and vectors, Martha Stampfer for providing HMEC184 cells, Wade Harper and David Morgan for the gift of recombinant baculoviruses, and Juliette Fivaz, Willy Krek, Richard Iggo, Matthias Peter, Viesturs Simanis, Michel Strubin, Jaromir Vlach and the other members of our group for discussions and technical help. N Lauper and L Richman were supported by a research grant from the Swiss National Science Foundation, and A Beck by a grant from the Human Frontiers Science Program, both to B Amati. B Amati was the recipient of a START fellowship from the Swiss National Science Foundation. JM Slinger-land was supported by Cancer Care Ontario. This work was funded in part by grants from the DOD US Army Breast Cancer Program and the Burroughs Wellcome Fund to J. M. Slingerland.",
year = "1998",
month = nov,
day = "19",
doi = "10.1038/sj.onc.1202477",
language = "English (US)",
volume = "17",
pages = "2637--2643",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "20",
}